(Q36555670)

14 August 2017

title

Overall and progression-free survival in metastatic melanoma: analysis of a single-institution database (English)

1 reference

14 August 2017

1 reference

8

Vernon K Sondak

1 reference

14 August 2017

M Aleem Khan

1

1 reference

14 August 2017

Stephanie Andrews

2

1 reference

14 August 2017

Roohi Ismail-Khan

3

1 reference

14 August 2017

Pamela N Munster

4

1 reference

14 August 2017

Steven Brem

5

1 reference

14 August 2017

Jeff King

6

1 reference

14 August 2017

Douglas S Reintgen

7

1 reference

14 August 2017

Adil I Daud

9

1 reference

14 August 2017

publication date

1 July 2006

1 reference

14 August 2017

1 reference

14 August 2017

volume

13

1 reference

14 August 2017

issue

3

1 reference

14 August 2017

page(s)

211-217

1 reference

14 August 2017

cites work

Cancer statistics, 2006

1 reference

https://api.crossref.org/works/10.1177%2F107327480601300308

Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480601300308

High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480601300308

Sequential biochemotherapy versus chemotherapy for metastatic melanoma: results from a phase III randomized trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480601300308

Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480601300308

Temozolomide: a novel oral alkylating agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480601300308

Temozolomide for advanced, metastatic melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480601300308

Phase II study of temozolomide plus thalidomide for the treatment of metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480601300308

Temozolomide plus thalidomide in patients with advanced melanoma: results of a dose-finding trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480601300308

Treatment of metastatic melanoma in the brain with temozolomide and thalidomide

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480601300308

Prognostic factors in metastatic melanoma: a pooled analysis of Eastern Cooperative Oncology Group trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480601300308

10.1177/107327480601300308

21 January 2018

Identifiers

DOI

0 references

1 reference